TORONTO--(BUSINESS WIRE)-- BenchSci, a leading provider of AI software for biopharma research and development, today announced a two-year enterprise agreement with argenx, a global immunology innovation company, to deploy EMET, BenchSci's agentic research environment for preclinical drug discovery, within the organization. Selected through a competitive evaluation led by argenx's own scientists, the agreement represents a significant milestone in BenchSci's expansion across European biopharma.

Under the agreement, scientists across argenx's global research organization will use EMET to support preclinical, computational, and drug development workflows.

BenchSci Announces Two-Year Enterprise Agreement with argenx to Advance AI-Driven Preclinical Drug Discovery

Business Wire